Several clinical trials have been conducted or are ongoing to evaluate the safety and efficacy of CEA-targeting CAR-T cell therapy in patients with advanced or metastatic esophageal cancer or gastric cancer. This evidence concerns the gene CEACAM5 and gastric cancer.